Clinical Presentations

In diabetes care, “therapeutic inertia” refers to the failure to escalate or modify treatment when a patient’s glucose control is suboptimal. Even now — when newer, more effective treatments and monitoring tools are widely available — therapeutic inertia in diabetes remains a stubborn barrier. Providers often wait too long before …

In this week's Homerun Slides, we conclude with a look at the future direction of diabetes apps.

In this week's Homerun Slides, compelling decision support for the use of diabetes apps.

In this week's Homerun Slides, mobile diabetes apps as an effective method to provide diabetes education and coaching.

In this week's Homerun Slides, more on the diabetes app as a tool to streamline processes and save time as well as money.

In this week's Homerun Slides, we determine what makes a diabetes app useful.

In this week's Homerun Slides, we begin taking a look at Adam Brown's presentation as he answers the question, "Can diabetes apps make our lives easier?"

Autoimmunity persists in many patients even many years after diagnosis: Studies in patients with long disease duration suggest that beta-cell function may persist long after diagnosis in a significant proportion of patients. There is also evidence suggesting the co-existence of some low level of regeneration with chronic autoimmunity, as islet autoimmunity may also persist or perhaps be reactivated years after diagnosis. Indeed, significant proportions (30–40%) of islet or pancreas transplant recipients express one or more autoantibodies when evaluated prior to transplantation. Moreover, persisting autoreactive T-cell responses detected prior to transplantation correlate with islet graft failure on follow-up.

In this week's Homerun Slides, another question from the Adrenal category in Dr. Claude Lardinois' Endocrinology Jeopardy! This week's clue: 44-year-old male with hypertension, headache, tachycardia, and hyperhidrosis.

In this week's Homerun Slides, we conclude this series with CGM categories from the FDA's perspective.